COVID-19 is, in the end, an endothelial disease European Heart Journal. Endolethial cell: “The main type of cell found in the inside lining of blood vessels, lymph vessels, and the heart.” From the abstract: ” SARS-CoV-2, the aetiological agent of COVID-19, causes the current pandemic. It produces protean manifestations ranging from head to toe, wreaking seemingly indiscriminate havoc on multiple organ systems including the lungs, heart, brain, kidney, and vasculature. This essay explores the hypothesis that COVID-19, particularly in the later complicated stages, represents an endothelial disease…. The concept of COVID-19 as an endothelial disease provides a unifying pathophysiological picture of this raging infection, and also provides a framework for a rational treatment strategy at a time when we possess an indeed modest evidence base to guide our therapeutic attempts to confront this novel pandemic.”
Influenza may facilitate the spread of SARS-CoV-2 (preprint) medRxiv. From the main text: “Respiratory viruses—including SARS-CoV-2 and other coronaviruses, rhinoviruses, influenza viruses, etc.—form a large class of viruses that cause seasonal infections of the respiratory tract in humans. Mounting evidence indicates that their epidemiologies are not independent, as a result of interaction mechanisms that may operate at different scales and that can be classified as either facilitatory or antagonistic.” • A preprint, a model, and heavily qualified. So I think South China Morning Post’s headline overstates.
America’s Coronavirus Endurance Test The New Yorker. “In retrospect, one of the biggest weaknesses in our pandemic planning was that many infectious-disease experts, including me, focussed on the threat posed by a novel strain of influenza. We feared a repeat of 1918—and yet, because we now have the technology to create and mass-produce a new flu vaccine in only a few months’ time, a flu pandemic isn’t necessarily the worst-case scenario. As we are currently discovering, designing and testing an entirely new vaccine against a never-before-seen infectious disease is a far more uncertain and daunting task. The fact that the novel coronavirus is RNA-based, like H.I.V., intensifies the difficulty. It’s possible that a vaccine will arrive this year—but many experts think that it could be two years or even longer before a safe and effective shot has been developed, tested, manufactured, and made widely available.”